Publication | Open Access

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

Breast OncologyMedicinePathologyPrimary ResistanceHer2 Genomic AmplificationCancer GenomicsBreast CancerEstrogen Receptor PositivityMolecular DiagnosticsOncologyRadiation OncologyTumor BiologyEndocrine-related Cancer